Hui-Mei Pang, Guang-Ming Huang, Xiao-Ling Qin, Hong-Liang Zhang, Si-Jun Wei
From the Department of Pharmacy, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi, China.
Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Indian J Dermatol. 2023 May-Jun;68(3):318-326. doi: 10.4103/ijd.ijd_343_22.
To investigate the regularity and characteristics of adverse drug reaction (ADR) of reactive cutaneous capillary endothelial proliferation caused by Camrelizumab, so as to provide reference for clinical rational use of drugs. Searching for case reports of Camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP) in databases such as China Biology Medicine disc, VIP Database, CNKI, Wanfang Medical, PubMed, Wiley online library, Embase with "Carritzumab/Ericab," "SHR-1210," "Reactive cutaneous capillary endothelial proliferation," "Reactive capillary hemangiomas," and "Capillary proliferation" as search terms. The retrieval time is from the establishment of the database to February 2022. After eliminating clinical trials and incomplete literature, information of patients included in the literature was analyzed, which included gender, age, reason for medication, usage and dosage, time of ADR, concomitant medication, clinical manifestations, intervention measures, outcomes of patients, etc. A total of 11 articles involving 16 patients were included, including 11 males and five females, with an average age of 60.5 years. Reasons for medication included nine cases of non-small cell lung cancer (NSCLC), four cases of liver cancer, one case of small cell lung cancer (SCLC), one case of synovial sarcoma, and one case of Hodgkin lymphoma. Thirteen patients recorded in detail that the dosage of Camrelizumab was 200 mg, and the frequency of medication was q2w~q4w. Eight patients were treated with Camrelizumab alone, and eight patients were treated with combined medication. RCCEP occurred in nine patients after the first medication, and in seven patients after two-four cycles of medication, the average medication cycle was two cycles, and the average occurrence time was 12.5 days after the last medication. The main clinical manifestations were that several different sizes of growths such as red nevus-like, pearl-like, and mulberry-like growths appear on the head, face, neck, torso, limbs, and other parts of the body, all of which were grade 1-2. The RCCEP of all patients was controlled after treatment. During the treatment, 11 patients were stable and five patients were local remission. RCCEP is caused by Camrelizumabis a special skin immune response, which will not cause life-threatening to patients. However, clinicians and pharmacists should be familiar with the characteristics and regularities of the adverse reaction, to do a good job in medication monitoring and management, as for ensuring the safety of patients with medication.
为探讨卡瑞利珠单抗引起的反应性皮肤毛细血管内皮增生不良反应（ADR）的规律及特点，以便为临床合理用药提供参考。以“卡瑞利珠单抗/艾瑞卡”“SHR-1210”“反应性皮肤毛细血管内皮增生”“反应性毛细血管瘤”“毛细血管增生”为检索词，在中国生物医学文献数据库、维普数据库、中国知网、万方医学网、PubMed、Wiley在线图书馆、Embase等数据库中检索卡瑞利珠单抗所致反应性皮肤毛细血管内皮增生（RCCEP）的病例报告。检索时间为各数据库建库至2022年2月。剔除临床试验及文献资料不完整的文献后，对纳入文献的患者信息进行分析，包括性别、年龄、用药原因、用法用量、ADR发生时间、合并用药情况、临床表现、干预措施、患者转归等。共纳入11篇文献，涉及16例患者，其中男性11例，女性5例，平均年龄60.5岁。用药原因包括非小细胞肺癌（NSCLC）9例、肝癌4例、小细胞肺癌（SCLC）1例、滑膜肉瘤1例、霍奇金淋巴瘤1例。13例患者详细记录卡瑞利珠单抗剂量为200mg，用药频次为q2wq4w。8例患者单用卡瑞利珠单抗治疗，8例患者联合用药。9例患者首次用药后发生RCCEP，7例患者在用药24个周期后发生，平均用药周期为2个周期，平均发生时间为末次用药后12.5天。主要临床表现为头面部、颈部、躯干、四肢等部位出现大小不等的红色痣样、珍珠样、桑葚样等多种皮疹，均为1~2级。所有患者的RCCEP经治疗后均得到控制。治疗期间，11例患者病情稳定，5例患者局部缓解。卡瑞利珠单抗引起的RCCEP是一种特殊的皮肤免疫反应，不会对患者造成生命威胁。但临床医生和药师应熟悉该不良反应的特点及规律，做好用药监测与管理，以确保患者用药安全。
